401 related articles for article (PubMed ID: 28675165)
1. Precision medicine based on epigenomics: the paradigm of carcinoma of unknown primary.
Moran S; Martinez-Cardús A; Boussios S; Esteller M
Nat Rev Clin Oncol; 2017 Nov; 14(11):682-694. PubMed ID: 28675165
[TBL] [Abstract][Full Text] [Related]
2. Epigenetics and Precision Oncology.
Werner RJ; Kelly AD; Issa JJ
Cancer J; 2017; 23(5):262-269. PubMed ID: 28926426
[TBL] [Abstract][Full Text] [Related]
3. Redefining cancer of unknown primary: Is precision medicine really shifting the paradigm?
Olivier T; Fernandez E; Labidi-Galy I; Dietrich PY; Rodriguez-Bravo V; Baciarello G; Fizazi K; Patrikidou A
Cancer Treat Rev; 2021 Jun; 97():102204. PubMed ID: 33866225
[TBL] [Abstract][Full Text] [Related]
4. Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management.
Greco FA
Curr Treat Options Oncol; 2013 Dec; 14(4):634-42. PubMed ID: 23990214
[TBL] [Abstract][Full Text] [Related]
5. New techniques to identify the tissue of origin for cancer of unknown primary in the era of precision medicine: progress and challenges.
Ma W; Wu H; Chen Y; Xu H; Jiang J; Du B; Wan M; Ma X; Chen X; Lin L; Su X; Bao X; Shen Y; Xu N; Ruan J; Jiang H; Ding Y
Brief Bioinform; 2024 Jan; 25(2):. PubMed ID: 38343328
[TBL] [Abstract][Full Text] [Related]
6. Cancer of Unknown Primary in the Molecular Era.
Kato S; Alsafar A; Walavalkar V; Hainsworth J; Kurzrock R
Trends Cancer; 2021 May; 7(5):465-477. PubMed ID: 33516660
[TBL] [Abstract][Full Text] [Related]
7. Progress in refining the clinical management of cancer of unknown primary in the molecular era.
Rassy E; Pavlidis N
Nat Rev Clin Oncol; 2020 Sep; 17(9):541-554. PubMed ID: 32350398
[TBL] [Abstract][Full Text] [Related]
8. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterisation and liquid biomarkers in Carcinoma of Unknown Primary (CUP): taking the 'U' out of 'CUP'.
Conway AM; Mitchell C; Kilgour E; Brady G; Dive C; Cook N
Br J Cancer; 2019 Jan; 120(2):141-153. PubMed ID: 30580378
[TBL] [Abstract][Full Text] [Related]
10. Cancer of unknown primary (CUP) through the lens of precision oncology: a single institution perspective.
Weiss L; Heinrich K; Zhang D; Dorman K; Rühlmann K; Hasselmann K; Klauschen F; Kumbrink J; Jung A; Rudelius M; Mock A; Ormanns S; Kunz WG; Roessler D; Beyer G; Corradini S; Heinzerling L; Haas M; von Bergwelt-Baildon M; Boeck S; Heinemann V; Westphalen CB
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8225-8234. PubMed ID: 37062035
[TBL] [Abstract][Full Text] [Related]
11. A Review on Cancer of Unknown Primary Origin: The Role of Molecular Biomarkers in the Identification of Unknown Primary Origin.
Yan N; Zhang Y; Guo X; Yuan D; Tian G; Yang J
Methods Mol Biol; 2020; 2204():109-119. PubMed ID: 32710319
[TBL] [Abstract][Full Text] [Related]
12. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
Dermawan JK; Rubin BP
Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
[TBL] [Abstract][Full Text] [Related]
13. Clinical epigenetics: seizing opportunities for translation.
Berdasco M; Esteller M
Nat Rev Genet; 2019 Feb; 20(2):109-127. PubMed ID: 30479381
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Profiling of CUP.
Cancer Discov; 2016 Nov; 6(11):1203. PubMed ID: 27658716
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoepigenetics: an element of personalized therapy?
Majchrzak-Celińska A; Baer-Dubowska W
Expert Opin Drug Metab Toxicol; 2017 Apr; 13(4):387-398. PubMed ID: 27860490
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic epigenetic biomarkers in cancer.
Costa-Pinheiro P; Montezuma D; Henrique R; Jerónimo C
Epigenomics; 2015; 7(6):1003-15. PubMed ID: 26479312
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive Genomic Profiling of Carcinoma of Unknown Primary Site: New Routes to Targeted Therapies.
Ross JS; Wang K; Gay L; Otto GA; White E; Iwanik K; Palmer G; Yelensky R; Lipson DM; Chmielecki J; Erlich RL; Rankin AN; Ali SM; Elvin JA; Morosini D; Miller VA; Stephens PJ
JAMA Oncol; 2015 Apr; 1(1):40-49. PubMed ID: 26182302
[TBL] [Abstract][Full Text] [Related]
18. Early Epigenetic Markers for Precision Medicine.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive biomarker diagnostics of unfavorable cancer of unknown primary to identify patients eligible for precision medical therapies.
Zaun G; Borchert S; Metzenmacher M; Lueong S; Wiesweg M; Zaun Y; Pogorzelski M; Behrens F; Schildhaus HU; Virchow I; Kasper S; Schuler M; Theurer S; Liffers S
Eur J Cancer; 2024 Mar; 200():113540. PubMed ID: 38316065
[TBL] [Abstract][Full Text] [Related]
20. Emerging epigenomic landscapes of pancreatic cancer in the era of precision medicine.
Lomberk G; Dusetti N; Iovanna J; Urrutia R
Nat Commun; 2019 Aug; 10(1):3875. PubMed ID: 31462645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
